|
Background: Relapse of CML on imatinib is most often
associated with point mutations in the BCR-ABL kinase domain. BMS-354825 is a
novel ABL kinase inhibitor with = 300-fold greater potency than imatinib and
preclinical activity against 14 of 15 imatinib resistant BCR-ABL mutants tested.
Unlike imatinib, BMS-354825 binds the ABL kinase domain in both active and
inactive conformations, and is thus predicted to have significant activity in
most imatinib-resistant CML and Ph+ ALL cases.
[BMS354825] A group for the BMS354825 clinical trial A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
